About Malegra DXT Plus 100/
Malegra DXT Plus 100/60 mg is a dual-component pharmaceutical compound combining sildenafil citrate (100mg) and duloxetine hydrochloride (60mg) manufactured by Sunrise Remedies for laboratory research applications. This combination formulation enables researchers to investigate the pharmacological interactions between phosphodiesterase type 5 inhibition and selective serotonin-norepinephrine reuptake inhibition pathways within controlled experimental frameworks. Scientists studying cardiovascular and neurochemical mechanisms can examine how these distinct mechanisms of action interact at the cellular level. The formulation provides a standardised platform for investigating dual-pathway modulation in various research models.
Laboratory Applications
Research teams examining vascular biology can utilise this compound to study nitric oxide pathway enhancement through PDE5 inhibition alongside monoamine neurotransmitter regulation via SNRI activity. The sildenafil component enables investigation of cyclic GMP signalling cascades, whilst the duloxetine component facilitates examination of serotonin and norepinephrine reuptake mechanisms in neural tissue samples. Cardiovascular researchers at Stroid UK Shop frequently analyse how these pathways interact within endothelial cell cultures. Studies examining dual-mechanism approaches to vascular function can benefit from this standardised formulation. Neurochemistry laboratories investigating monoamine system interactions with vascular signalling find particular value in this research tool. The compound’s dual-active design enables comparative studies between single-pathway and combined-pathway interventions. Researchers can examine dose-response relationships for both components simultaneously within experimental protocols.
Research Specifications
| Parameter | Specification |
|---|---|
| Active Components | Sildenafil Citrate 100mg, Duloxetine HCl 60mg |
| Manufacturer | Sunrise Remedies |
| Form | Oral tablet |
| Storage | Room temperature, dry conditions |
| Shelf Life | As per manufacturer specifications |
| Solubility | Verify with supplier for research solvents |
This dual-active formulation provides researchers access to both established pharmaceutical compounds within a single dosage unit, streamlining experimental protocols requiring combined pathway investigation. Scientists working with other drugs containing sildenafil and duloxetine can compare this specific combination against alternative formulations.
Compliance Statement
Malegra DXT Plus 100/60 mg is supplied strictly for in-vitro research purposes only and is not intended for human consumption or therapeutic use. Researchers must ensure appropriate laboratory safety protocols when handling this compound. UK research institutions studying vascular biology alongside SARMs and peptides should maintain proper documentation of experimental use. This product requires appropriate research licensing and should only be handled by qualified laboratory personnel following institutional safety guidelines.
